Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jun 15;67(6):e0037423.
doi: 10.1128/aac.00374-23. Epub 2023 May 8.

In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones

Sunish Shah  1 , Lloyd G Clarke  1 , Kathleen K Adams  2
Affiliations
Multicenter Study

In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones

Sunish Shah et al. Antimicrob Agents Chemother. .

Abstract

Results from this large, multicenter study suggest that patients with a confirmed ciprofloxacin, moxifloxacin, or levofloxacin hypersensitivity reaction are likely to tolerate other fluoroquinolones. Avoiding different fluoroquinolones in patients labeled with a ciprofloxacin, moxifloxacin, or levofloxacin allergy may not always be mandatory. This was a study of patients with a ciprofloxacin, moxifloxacin, or levofloxacin hypersensitivity reaction and a documented electronic medical record administration of a different fluoroquinolone. Numerically, the most common reaction risk occurred with a challenge to moxifloxacin (2/19; 9.5%), followed by ciprofloxacin (6/89; 6.3%), and levofloxacin (1/44; 2.2%).

Keywords: allergy; cross-reactivity; fluoroquinolone; hypersensitivity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. CLSI. 2018. Performance standards for antimicrobial disk susceptibility tests. 13th ed. CLSI Standard M02. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. González-Gregori R, Hernández Fernandez De Rojas MD, López-Salgueiro R, Díaz-Palacios M, García AN. 2012. Allergy alerts in electronic health records for hospitalized patients. Ann Allergy Asthma Immunol 109:137–140. doi:10.1016/j.anai.2012.06.006. - DOI - PubMed
    1. Lobera T, Audícana MT, Alarcón E, Longo N, Navarro B, Muñoz D. 2010. Allergy to quinolones: low cross-reactivity to levofloxacin. J Invest Allergol Clin Immunol 20:607–611. - PubMed
    1. Demir S, Gelincik A, Akdeniz N, Aktas-Cetin E, Olgac M, Unal D, Ertek B, Coskun R, Colakoğlu B, Deniz G, Buyukozturk S. 2017. Usefulness of in vivo and in vitro diagnostic tests in the diagnosis of hypersensitivity reactions to quinolones and in the evaluation of cross-reactivity: a comprehensive study including the latest quinolone gemifloxacin. Allergy Asthma Immunol Res 9:347–359. doi:10.4168/aair.2017.9.4.347. - DOI - PMC - PubMed
    1. Azimi SF, Mainella V, Jeffres MN. 2022. Immediate hypersensitivity to fluoroquinolones: a cohort assessing cross-reactivity. Open Forum Infect Dis 9:ofac106. doi:10.1093/ofid/ofac106. - DOI - PMC - PubMed

Publication types